

Aspergillus GM

Lateral Flow Assay



REF: AF2003

CE : Serum, BAL

It's About Time



**45 MIN
to Results!**



The LFA could aid in quick clinical decisions in ICU patients, which could lead to increased survival of patients with true IPA.⁵

The IMMY sōna *Aspergillus* galactomannan LFA has been suggested as a diagnostic tool in the 2020 ECMM CAPA-IAA-ICU management algorithm guidelines.¹

Good agreement to existing product, better agreement to EORTC (true disease status):

Performance of IMMY ASP LFA	Specimen	Sensitivity	Specificity	NPV
vs. Proven IA ²	Serum & BAL	100%	95.5%	
vs. Probable IA ²	Serum & BAL	87.5%	96.2%	
vs. Proven IPA ³	BAL	91%	92%	99%
vs. EORTC/MSG ⁴	Serum	91%	91%	
vs. 2008 EORTC/MSG ⁵	BAL	88%	81%	94%
vs. EORTC excluding GM ⁵	BAL	100%	81%	96%
vs. AsplCU ⁵	BAL	94%	81%	97%
vs. modified AsplCU ⁵	BAL	87%	81%	94%
vs. modified AsplCU excluding GM ⁵	BAL	97%	81%	98%


1. ECMM. COVID-19/Influenza-Associated Pulmonary Aspergillosis – Management. 2020

2. Jani K, McMillen T, Morjaria S, Babady NE. Performance of the sōna *Aspergillus* Galactomannan Lateral Flow Assay in a Cancer Patient Population. J Clin Microbiol. 2021; JCM0059821.

3. Mercier T, et al. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Med Mycol. 2019.

4. Serin I, Dogu MH. Serum *Aspergillus* galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: A single-centre study. Mycoses. 2021;64(6):678-683.

5. Mercier T, et al. Point of care aspergillus testing in intensive care patients. Crit Care. 2020.



LFA Cube Reader provides objective numeric value and allows for easy batch testing.

CONTACT US

Ready to evaluate today?
Contact us for a validation kit now.